CAR-T疗法在卵巢癌中的应用前景

doi:10.11904/j.issn.1002-3070.2021.01.012

Abstract

Abstract: Ovarian cancer(OC)is the most deadly gynecological tumor.Because of its long onset latency and lack of early diagnosis,most patients are already in advanced stage at the time of initial treatment.In addition to the conventional surgical chemotherapy,in recent years,chimeric antigen receptor modified T cells(CAR-T)have received considerable attention in the research field of tumor system therapy.Various preclinical experiments and clinical trials have confirmed that CAR-T cell immunotherapy is a promising treatment for OC,and it shows the advantages that are different from other solid tumors,but it still needs to face many challenges.In this review,we will systematically introduce the latest research progress of CAR-T cell immunotherapy,including the biological understanding of CAR-T cell therapy,clinical application,challenges faced and possible strategies to improve the therapeutic effect.

Key words: Ovarian cancer, CAR-T cell therapy, Gene editing technology, Cytokine release syndrome, On-target-extratumor toxicity

CLC Number:

R737.31

ZHANG Wenwen,JIANG Liangliang,WANG Jing. Application prospect of CAR-T therapy in ovarian cancer[J]. Journal of Practical Oncology, 2021, 35(1): 59-63.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.01.012

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I1/59

References

1 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
2 Rizzuto I,Stavraka C,Chatterjee J,et al.Risk of ovarian cancer relapse score:aprognostic algorithm to predict relapse following treatment for advanced ovarian cancer[J].Int J Gynecol Cancer,2015,25(3):416-22.
3 Batlevi CL,Matsuki E,Brentjens RJ,et al.Novel immunotherapies in lymphoid malignancies[J].Nat Rev Clin Oncol,2016,13(1):25-40.
4 Wang Z,Chen W,Zhang X,et al.A long way to the battlefront:CAR T cell therapy against solid cancers[J].J Cancer,2019,10(14):3112-3123.
5 Baumeister SH,Murad J,Werner L,et al.Phase 1 trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma[J].Cancer Immunol Res,2019,7(1):100-112.
6Brown CE,Aguilar B,Starr R,et al.Optimization of IL13Rα2-targeted chimeric antigen receptor T cells for improved persistence and antitumor efficacy against glioblastoma[J].Mol Ther,2018,26(1):31-44.
7 Harris DT,Kranz DM,Adoptive T.Cell therapies:a comparison of T cell receptors and chimeric antigen receptors[J].Trends Pharmacol Sci,2015,37(3):220-230.
8 Xu X,Qiu J,Sun Y.The basics of CAR-T design and challenges in immunotherapy of solid tumors ovarian cancer as a model[J].Hun Vaccin Immunother,2017,13(7):1548-1555.
9 Gross G,Waks T,Eshhar Z,et al.Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity[J].Proc Natl Acad Sci U S A,1989,86(24):10024-10028.
10 Kawalekar OU,O'connor RS,Fraietta JA,et al.Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR-T cells[J].Immunity,2016,44(2):380-390.
11 Hay KA,Turtle CJ.Chimeric antigen receptor(CAR)T cells:lessons learned from targeting of CD19 in B-cell malignancies[J].Drugs,2017,77(3):237-245.
12 Zhang Q,Zhang Z,Peng M,et al.CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma:from bench to bedside[J].OncoImmunology,2016,5(12):e1251539.
13 Chen N,Li X,Chintala NK,et al.Driving CARs on the uneven road of antigen heterogeneity in solid tumors[J].Curr Opin Immunol,2018,51:103-110.
14 Ebert LM,Yu W,Gargett T,et al.Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology[J].Biochem Soc T,2018,46(2):391-401.
15 Annesley CE,Summers C,Ceppi F,et al.The evolution and future of CART cells for B-cell acute lymphoblastic leukemia[J].Clin Pharmacol Ther,2018,103(4):591-598.
16 Mauro C,Keisuke W,June CH,et al.Driving cars to the clinic for solid tumors[J].Gene Ther,2018,25(3):165-175.
17 Westwood JA,Smyth MJ,Teng MW,et al.Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice[J].Proc Natl Acad Sci U S A,2005,102(52):19051-19056.
18 Jamali A,Kapitza L,Schaser T,et al.Highly efficient and selective CAR-gene transfer using CD4-and CD8-targeted lentiviral vectors[J].Mol Ther Methods Clin Dev,2019,13:371-379.
19 Wu H,Wang K,Liu W,et al.Recombinant adenovirus-mediated overexpression of PTEN and KRT10 improves cisplatin resistance of ovarian cancer in vitro and in vivo[J].Genet Mol Res,2015,14(2):6591-6597.
20 Kim CK,Haider KH,Choi SH,et al.Nonviral vector for efficient gene transfer to human ovarian adenocarcinoma cells[J].Gynecol Oncol,2002,84(1):85-93.
21 Wiesinger M,Mrz J,Kummer M,et al.Clinical-scale production of CAR-T cells for the treatment of melanoma patients by mRNA transfection of a CSPG4-specific CAR under full GMP compliance[J].Cancers(Basel),2019,11(8):2072-2094.
22 Hudecek M,Izsvák Z,Johnen S,et al.Going non-viral:the sleeping beauty transposon system breaks on through to the clinical side[J].Crit Rev Biochem Mol Biol,2017,52(4):355-380.
23 Sapranauskas R,Gasiunas G,Fremaux C,et al.The streptococcus thermophilus CRISPR/Cas system provides immunity in escherichia coli[J].Nucl Acids Res,2011,39(21):9275-9282.
24 Charpentier E,Doudna JA.Biotechnology:rewriting a genome[J].Nature,2013,495(7439):50-51.
25 Adli M.The CRISPR tool kit for genome editing and beyond[J]. Nat Commun,2018,9(1):1911.
26 Eyquem J,Mansilla-Soto J,Giavridis T,et al.Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection[J].Nature,2017,543(7643):113-117.
27 Roth TL,Puig-Saus C,Yu R,et al.Reprogramming human T cell function and specificity with non-viral genome targeting[J].Nature,2018,559(7714):405-409.
28 Seki A,Rutz S.Optimized RNP transfection for highly efficient CRISPR/Cas9-mediated gene knockout in primary T cells[J].J Exp Med,2018,215(3):985-997.
29 Cho SW,Kim S,Kim Y,et al.Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases[J].Genome Res,2014,24(1):132-141.
30 Salas-Mckee J,Kong W,Gladney WL,et al.CRISPR/Cas9-based genome editing in the Era of CAR T cell immunotherapy[J].Hum Vaccin Immunother,2019,15(5):1126-1132.
31 Zhu X,Cai H,Zhao L,et al.CAR-T cell therapy in ovarian cancer:from the bench to the bedside[J].Oncotarget,2017,8(38):64607-64621.
32 Owens GL,Sheard VE,Kalaitsidou M,et al.Preclinical assessment of CAR T-Cell therapy targeting the tumor antigen 5T4 in ovarian cancer[J].J Immunother,2018,41(3):130-140.
33 Hwu P,Shafer GE,Treisman J,et al.Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the fc receptor gamma chain[J].J Exp Med,1993,178(1):361-366.
34 Chatterjee M,Mohapatra S,Ionan A,et al.Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays[J].Cancer Res,2006,66(2):1181-1190.
35 Rodriguez-Garcia A,Sharma P,Poussin M,et al.CAR T-cells targeting müllerian inhibiting substance type 2 receptor for the treatment of ovarian cancer and other gynecologic malignancies[J].Mol Ther,2020,28(2):548-560.
36 Coelho R,Marcos-Silva L,Ricardo S,et al.Peritoneal dissemination of ovarian cancer:role of MUC16-mesothelin interaction and implications for treatment[J].Expert Rev Anticancer Ther,2018,18(2):177-186.
37 Santoro SP,Kim S,Motz GT,et al.T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression[J].Cancer Immunol Res,2015,3(1):68-84.
38 John PM,Anna KK,Hee JL,et al.Effective targeting of TAG72+peritoneal ovarian tumors via regional delivery of CAR-engineered T cells[J].Front Immunol,2018,9:2268.
39 Tanyi JL,Stashwick C,Plesa G,et al.Possible compartmental cytokine release syndrome in a patient with recurrent ovarian cancer after treatment with mesothelin-targeted CAR-T Cells[J].J Immunother,2017,40(3):104-107.
40 Whilding LM,Halim L,Draper B,et al.CAR T-cells targeting the integrin αvβ6 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies[J].Cancers(Basel),2019,11(5):674.
41 Drent E,Themeli M,Poels R,et al.A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization[J].Mol Ther,2017,25(8):1946-1958.
42 Caruso HG,Hurton LV,Najjar A,et al.Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity[J].Cancer Res,2015,75(17):3505-3518.
43 Jensen MC,Riddell SR.Designing chimeric antigen receptors to effectively and safely target tumors.[J].Curr Opin Immunol,2015,33:9-15.
44 Roybal KT,Rupp LJ,Morsut L,et al.Precision tumor recognition by T cells with combinatorial antigen-sensing circuits[J].Cell,2016,164(4):770-779.
45 Deng C,Zhao J,Zhou S,et al.The vascular disrupting agent CA4P improve the antitumor efficacy of CAR-T cells in preclinical models of solid human tumors[J].Mol Ther,2020,28(1):75-88.
46 Coon ME,Stephan SB,Gupta V,et al.Nitinol thin films functionalized with CAR-T cells for the treatment of solid tumours[J].Nat Biomed Eng,2020,4(2):195-206.
47 Gargett T,Yu W,Dotti G,et al.GD2-specific CAR-T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade[J].Mol Ther,2016,24(6):1135-1149.
48 Ma L,Dichwalkar T,Chang JYH,et al.Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor[J].Science,2019,365(6449):162-168.

[1]	HOU Jianying,ZHU Wei. Research progress of immunosuppressive PD-1/PD-L1 in treatment of ovarian cancer [J]. Journal of Practical Oncology, 2020, 34(3): 266-270.
[2]	LIANG Yongqin, ZHAO Hongwei. Application progress of antiangiogenic drugs in platinum-resistant ovarian cancer [J]. Journal of Practical Oncology, 2020, 34(1): 60-63.
[3]	HUANG Li, LONG Youmei, FU Yixia, XIA Liangbin. Effect of pterostilbene on apoptosis and glycolysis of ovarian cancer SKOV3 cells and its mechanism [J]. Journal of Practical Oncology, 2019, 33(6): 502-507.
[4]	DENG Mingxin, ZHANG Ying. Research progress of circRNAs and ovarian cancer [J]. Journal of Practical Oncology, 2019, 33(6): 549-552.
[5]	ZHANG Huiting, LOU Ge. Research progress in 3D cell culture model of ovarian cancer tumor microenvironment [J]. Journal of Practical Oncology, 2019, 33(6): 557-560.
[6]	SONG Ling, FU Qiong. Astragalin inhibits hypoxia-induced proliferation and invasion of ovarian cancer cells by up-regulating PHD2 [J]. Journal of Practical Oncology, 2019, 33(5): 407-414.
[7]	ZHANG Beilei, LI Yi, WU Tao, JIANG Feng, ZHAO Hongxi, LI Yanhong. Mechanism study of sanguinarine inhibiting tumor growth of ovarian cancer by apoptosis induction [J]. Journal of Practical Oncology, 2019, 33(4): 305-309.
[8]	LV Bowen, QIAN Jun, WANG Jie, QIAN Jingrong, LU Yingying, SU Liju, YANG Tongshu, LI Wenhui. Expression of MiR-455-5p in epithelial ovarian cancer and its target gene function [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 115-121.
[9]	SONG Ling, FU Qiong. Study of the effect of astragalin on proliferation of ovarian cancer cells by inhibiting the glycolytic pathway induced Via HIF-1α [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 503-509.
[10]	JIANG Liangliang, WANG Jing. Progress in diagnosis and treatment of distant metastasis of epithelial ovarian cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 480-482.
[11]	LIANG Guanying,CHI Qiujun,LI Xiaomei. Effect and mechanism of Vorinostat on the proliferation and apoptosis of ovarian cancer SKOV3 cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 298-302.
[12]	LI Wenhui, LV Bowen, QIAN Jun, SU Liju, YANG Tongshu, QIAN Jingrong, WANG Jie. Effect of microRNA-150 on proliferation,apoptosis,invasion and metastasis of epithelial ovarian cancer cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 208-213.
[13]	BI Qiling, ZHOU Lihong, HAN Yimin. Research progress of HOX gene and gynecologic tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 140-143.
[14]	LIU Xin, XU Yingjuan, YANG Chang, LOU Ge. Research progress on cadherins and integrins in ovarian epithelial cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 548-553.
[15]	YU Ge,SUN Jianing,FENG Xiaoling. Expression of PSMD10 and Ki67 in epithelial ovarian carcinoma and its clinicopathological significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 112-116.

Application prospect of CAR-T therapy in ovarian cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments